D Betticher
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
Strasser F, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Ann Oncol 2015
Dec 8, 2015The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
Dec 8, 2015Ann Oncol 2015
Strasser Florian, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK)
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
von Rohr A, Tobler A, Betticher D, Cerny T, Fey M, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9.
Oct 1, 2002Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
Oct 1, 2002Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9
von Rohr A, Tobler A, Betticher D, Cerny Thomas, Fey M F, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S-F H, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells
Pichert G, Stahel R, Schmitter D, Stupp R, Betticher D, Cogliatti S, Cerny T, Hess U, Schmitz S, Ghielmini M. Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells. Clinical lymphoma 2001; 1:293-7.
Mar 1, 2001Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells
Mar 1, 2001Clinical lymphoma 2001; 1:293-7
Pichert G, Stahel R A, Schmitter D, Stupp R, Betticher D, Cogliatti S B, Cerny Thomas, Hess U, Schmitz S F, Ghielmini M
Role of high-dose therapy in diffuse large B-cell lymphoma
Cerny T, Betticher D. Role of high-dose therapy in diffuse large B-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11 Suppl 3:117-21.
Jan 1, 2000Role of high-dose therapy in diffuse large B-cell lymphoma
Jan 1, 2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11 Suppl 3:117-21
Cerny Thomas, Betticher D